Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 14, Issue 8, Pages 15885-15909
Publisher
MDPI AG
Online
2013-07-30
DOI
10.3390/ijms140815885
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antiangiogenic Therapies in Epithelial Ovarian Cancer
- (2017) Deanna G. K. Teoh et al. Cancer Control
- Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer
- (2013) Ernest S. Han et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
- (2013) Tina Sharma et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- breast cancer, early stage
- (2012) T. S. K. Mok et al. ANNALS OF ONCOLOGY
- Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
- (2012) G Freyer et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Role of angiogenesis in the pathogenesis of cancer
- (2012) Paulo M. Hoff et al. CANCER TREATMENT REVIEWS
- Anti-Angiogenic Approaches to Malignant Gliomas
- (2012) R. Soffietti et al. CURRENT CANCER DRUG TARGETS
- Novel targets for VEGF-independent anti-angiogenic drugs
- (2012) Marco Petrillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer
- (2012) Teresa Troiani et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cediranib: a VEGF receptor tyrosine kinase inhibitor
- (2012) Marina Sahade et al. Future Oncology
- Ovarian low-grade serous carcinoma: A comprehensive update
- (2012) Ivan Diaz-Padilla et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
- (2012) Susana M. Campos et al. GYNECOLOGIC ONCOLOGY
- Clinical trials and future potential of targeted therapy for ovarian cancer
- (2012) Hiroaki Itamochi et al. International Journal of Clinical Oncology
- Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer
- (2012) Deanna Teoh et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting angiogenesis in the pathological ovary
- (2012) W. Colin Duncan et al. REPRODUCTION FERTILITY AND DEVELOPMENT
- Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer
- (2011) Kathryn F. McGonigle et al. CANCER
- Bevacizumab and ovarian cancer
- (2011) Shinya Sato et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- The role of targeted therapy in ovarian cancer
- (2011) Susana Banerjee et al. EUROPEAN JOURNAL OF CANCER
- Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
- (2011) Kazuya Kudoh et al. GYNECOLOGIC ONCOLOGY
- Overview of anti-angiogenic agents in development for ovarian cancer
- (2011) Robert A. Burger GYNECOLOGIC ONCOLOGY
- Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
- (2011) Bengt Sorbe et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
- (2011) Robert L Coleman et al. LANCET ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
- (2011) R Grepin et al. ONCOGENE
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
- (2010) Robert J. Kurman et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma
- (2010) Hanan AlSaeid Alshenawy Annals of Diagnostic Pathology
- Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma
- (2010) Aref Agheli et al. ANTI-CANCER DRUGS
- Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling
- (2010) Noriomi Matsumura et al. CANCER SCIENCE
- VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis
- (2010) Luqing Zhang et al. CELL RESEARCH
- Lymphangiogenesis and cancer metastasis
- (2010) Mahir et al. Frontiers in Bioscience-Landmark
- FGFR2 mutations are rare across histologic subtypes of ovarian cancer
- (2010) Sara A. Byron et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Angiopoietin-2 Stimulation of Endothelial Cells Induces αvβ3 Integrin Internalization and Degradation
- (2010) Markus Thomas et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
- (2010) Ahmed Ashour Ahmed et al. JOURNAL OF PATHOLOGY
- Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect
- (2010) Maria Spiliotaki et al. LUNG CANCER
- Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
- (2010) D. G. Duda et al. ONCOLOGIST
- (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
- (2010) P. Hamberg et al. ONCOLOGIST
- Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
- (2010) Alfonso Sánchez-Muñoz et al. ONCOLOGY
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
- (2009) Beverly L. Falcón et al. AMERICAN JOURNAL OF PATHOLOGY
- A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
- (2009) A. du Bois et al. ANNALS OF ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas
- (2009) K.-T. Kuo et al. CANCER RESEARCH
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- (2009) A. Gregory Sorensen et al. CANCER RESEARCH
- The Role of Fibroblast Growth Factors in Tumor Growth
- (2009) M. Korc et al. CURRENT CANCER DRUG TARGETS
- Ovarian carcinoma pathology and genetics: recent advances
- (2009) C. Blake Gilks et al. HUMAN PATHOLOGY
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)
- (2009) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium
- (2009) H. T. Yuan et al. MOLECULAR AND CELLULAR BIOLOGY
- Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
- (2008) Chunhua Lu et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy
- (2008) ELENA FAVARO et al. APMIS
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
- (2008) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Cost of Care for Elderly Cancer Patients in the United States
- (2008) K. Robin Yabroff et al. JNCI-Journal of the National Cancer Institute
- Angiogenesis as a strategic target for ovarian cancer therapy
- (2008) Whitney A Spannuth et al. Nature clinical practice. Oncology
- Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting
- (2008) Kristian Pietras et al. PLOS MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now